Omeros Corporation (0KBU)
London Exchange · UK · prices in USD · close of 23 Oct 2026
Key indicators
| Last close | USD 16.55 |
|---|---|
| 52-week range | 6.86 – 21.48 |
| Return, 1 month / 3 months | −19.6% / +61.9% |
| Return, 1 year / 3 years | – / – |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 39 |
| Volatility (1 year) | 95.7% |
| Worst drawdown (1 year) | -50.5% |
| Average daily value traded | 0.10M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Omeros Corporation is a biopharmaceutical company based in Seattle, Washington, that discovers and develops small-molecule and protein therapeutics. Its marketed product is an additive used in irrigation solutions during eye surgery, and its research pipeline has focused on inflammation, complement-mediated disorders and conditions affecting the central nervous system. The company serves physicians, hospitals and surgical centres that use its ophthalmic product, while its development programmes address unmet medical needs across several therapeutic areas.
The shares are listed on the London Exchange in UK under the code 0KBU, and the price on this page is in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Omeros Corporation (0KBU) trades on the London Exchange in UK. It last closed at USD 16.55 on 23 October 2026.
Its price-based Market X-Ray is 56 out of 100 (a fair price profile), ranking 1,663 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 78 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 24.3% | ||
| From 52-week high | -20.5% | ||
| Momentum | 92 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 61.9% | ||
| 6-month return | 24.5% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 13 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 95.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -50.5% | ||
| Liquidity | 30 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.10M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +3.0% |
|---|---|
| 1 month | −19.6% |
| 3 months | +61.9% |
| 6 months | +24.5% |
| 1 year | – |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 18.53 / 13.31 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.81 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.